A Leap into the subgroups
On a wing and a prayer Leap heads for phase 3.
Zentalis doubles down on Wee1
But the new focus on a predictive biomarker could cut the market in half.
ASCO-GI – ALX resurrects evorpacept
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
ASCO-GI – a second colorectal win for Bristol's combo
Opdivo and Yervoy succeed again, but the US path remains unclear.
ASCO-GI – Exelixis’s son of Cabometyx disappoints
The company might need something better to replace its ageing blockbuster.
